PTGX
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
P/S 146.96; Graham Number N/A due to lack of earnings
- P/S ratio is unsustainable by traditional standards
- P/B ratio is highly inflated
Growth is binary, tied to FDA approval rather than current revenue
- Icotyde projected 2026 launch
- Rusfertide Breakthrough Therapy designation
- Dependence on third-party partners for commercialization
Historical price action reflects successful clinical progression
- Strong 1Y (+129%) and 5Y (+306%) price appreciation
- Inconsistent earnings surprise track record
Strong balance sheet provides a significant runway for R&D
- Piotroski F-Score 7/9
- Very low leverage
- High cash-to-debt ratio
Standard for clinical-stage biotechnology
- No dividend policy
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PTGX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics, Inc.
Primary
|
+306.1% | +356.6% | +129.0% | +36.8% | +9.2% | +7.2% |
|
GRFS
Grifols, S.A.
Peer
|
-51.1% | +11.6% | +28.0% | -11.9% | +2.2% | -0.4% |
|
ACLX
Arcellx, Inc.
Peer
|
+580.9% | +279.9% | +59.8% | +50.1% | +63.7% | +0.1% |
|
HQY
HealthEquity, Inc.
Peer
|
+11.9% | +34.2% | -2.5% | -13.9% | -0.8% | -7.9% |
|
RGEN
Repligen Corporation
Peer
|
-39.7% | -30.0% | -7.4% | -11.9% | -5.7% | +1.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PTGX
Protagonist Therapeutics, Inc.
|
NEUTRAL | $6.76B | - | -20.2% | -282.8% | $105.98 | |
|
GRFS
Grifols, S.A.
|
NEUTRAL | $6.74B | 12.83 | 6.2% | 5.3% | $8.21 | Compare |
|
ACLX
Arcellx, Inc.
|
BEARISH | $6.69B | - | -53.4% | -% | $114.39 | Compare |
|
HQY
HealthEquity, Inc.
|
NEUTRAL | $6.66B | 31.69 | 10.2% | 16.4% | $77.96 | Compare |
|
RGEN
Repligen Corporation
|
NEUTRAL | $6.64B | 137.0 | 2.4% | 6.6% | $117.82 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-26 | ALI ASIF | Chief Financial Officer | Sale | 24,765 | $2,581,504 |
| 2026-03-26 | ALI ASIF | Chief Financial Officer | Option Exercise | 24,765 | $438,280 |
| 2026-03-26 | SELICK HAROLD E | Director | Sale | 24,000 | $2,520,000 |
| 2026-03-26 | SELICK HAROLD E | Director | Option Exercise | 24,000 | $309,120 |
| 2026-03-26 | MOLINA ARTURO MD | Officer | Sale | 15,000 | $1,571,850 |
| 2026-03-26 | MOLINA ARTURO MD | Officer | Option Exercise | 15,000 | $120,600 |
| 2026-03-25 | PATEL DINESH V | Chief Executive Officer | Sale | 54,700 | $5,524,700 |
| 2026-03-25 | PATEL DINESH V | Chief Executive Officer | Option Exercise | 54,700 | $469,326 |
| 2026-03-23 | PATEL DINESH V | Chief Executive Officer | Gift | 50,000 | - |
| 2026-02-17 | WILLIAMS LEWIS T | Director | Sale | 18,000 | $1,483,560 |
| 2026-02-17 | WILLIAMS LEWIS T | Director | Option Exercise | 18,000 | $195,120 |
| 2026-02-06 | WADDILL WILLIAM D | Director | Sale | 20,000 | $1,673,600 |
| 2026-02-06 | WADDILL WILLIAM D | Director | Option Exercise | 20,000 | $166,200 |
| 2026-01-27 | ALI ASIF | Chief Financial Officer | Sale | 46,203 | $3,841,037 |
| 2026-01-27 | ALI ASIF | Chief Financial Officer | Option Exercise | 28,000 | $453,080 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
Protagonist Therapeutics is advancing a pipeline in inflammation, hematology, and metabolic diseases, highlighted by Rusfertide in Phase 3 and Icotyde, which is pending FDA/EMA approval for a projected 2026 US launch through partner Janssen. The company's financial prospects are heavily dependent on the successful regulatory approval and commercialization of these lead candidates. Consequently, the investment remains speculative due to significant risks associated with clinical development and regulatory outcomes.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning PTGX from our newsroom.